… ProQR Announces Strategic Changes to the Management Team and … said Daniel A. de Boer, chief executive officer of ProQR. “As we are moving into late stage development we are … reporting to David Rodman, MD, Executive Vice President of R&D. Aniz is an experienced ophthalmologist and has over 20 …
… ProQR Therapeutics Announces Results for the Fourth Quarter … said Daniel de Boer, Chief Executive Officer of ProQR. "We have advanced QR-010 through preclinical … the Company's IPO on the Nasdaq Global Market, a grant to ProQR's protection foundation, and increased costs reflecting …
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES … & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy
… ProQR to Present Axiomer RNA Editing Platform Technology at … & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Platenburg, co-founder and Chief Innovation Officer of ProQR. “With this approach disease-causing mutations can be …
ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5Rx, jetzt QR-1123, für autosomal-dominante Retinitis pigmentosa (adRP), eine seltene vererbte Form der Blindheit ohne zugelassene Therapie